Abstract: The invention relates to bioactive compounds purified from mycelium of Antrodia camphorata and the manufacturing method thereof. A method for treatment of cancers by administrating an effective amount of the said compounds selected from the group consisting of AC006, AC007, AC009, AC011, AC012, AC007-H1, AC009-H1, and AC012-H1 wherein the cancers is liver cancer, brain cancer, prostate cancer, breast cancer, colorectal cancer, or melanoma.
Abstract: Spirocyclic cyclohexane compounds corresponding to formula I a method for producing them, pharmaceutical compositions containing them, and methods of using them.
Type:
Grant
Filed:
July 21, 2015
Date of Patent:
January 9, 2018
Assignee:
Gruenenthal GmbH
Inventors:
Claudia Hinze, Otto Aulenbacher, Bernd Sundermann, Stefan Oberboersch, Elmar Friderichs, Werner Englberger, Babette-Yvonne Koegel, Klaus Linz, Hans Schick, Helmut Sonnenschein, Birgitta Henkel, Valerie Sarah Rose, Michael Jonathan Lipkin
Abstract: Methods of decreasing muscle function decline and improving muscle function in a subject are provided. The methods utilize an effective amount of epigallocatechin-3-gallate (EGCg) to increase the level of muscle vascular endothelial growth factor A (VEGF), to decrease myostatin levels, or both, and thereby decrease muscle function decline or improve muscle function. The EGCg may be provided as part of a nutritional composition.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
December 19, 2017
Assignee:
ABBOTT LABORATORIES
Inventors:
Sean Garvey, Suzette Pereira, Neile Edens
Abstract: A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
November 19, 2015
Date of Patent:
November 21, 2017
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Raphaelle Berger, Guizhen Dong, Subharekha Raghavan, Zhiqiang Yang
Abstract: Provided herein are solid forms comprising (a) 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (Lenalidomide) and (b) a coformer. Pharmaceutical compositions comprising the solid forms and methods for treating, preventing and managing various disorders are also disclosed.
Type:
Grant
Filed:
March 25, 2014
Date of Patent:
November 7, 2017
Assignee:
Celgene Corporation
Inventors:
G. Patrick Stahly, David Jonaitis, Ho-Wah Hui, Kevin J. Klopfer
Abstract: The present invention relates to a novel process for the preparation of 9-dichloromethylene-1,2,3,4-tetrahydro-1,4-methano-naphthalen-5-ylamine which process comprises a) reacting cyclopentadiene in the presence of a radical initiator and CXCl3, wherein X is chloro or bromo, to a compound of formula II aa) reacting cyclopentadiene with CXCl3, wherein X is chloro, in the presence of a metal catalyst to a compound of formula II wherein X is chloro, b) reacting the compound of formula II with a base in the presence of an appropriate solvent to the compound of formula III c) and converting the compound of formula III in the presence of 1,2-dehydro-6-nitrobenzene to the compound of formula IV and d) hydrogenating the compound of formula IV in the presence of a metal catalyst.
Type:
Grant
Filed:
January 23, 2015
Date of Patent:
October 24, 2017
Assignee:
Syngenta Crop Protection, LLC
Inventors:
Denis Gribkov, Bjorn Antelmann, Fanny Giordano, Harald Walter, Alain De Mesmaeker
Abstract: This invention relates to compounds of Formula (I) wherein Cy1, L1, Y, R1, L2, and Ar2 are defined herein, for the treatment of cancers, inflammatory disorders, and neurological conditions.
Type:
Grant
Filed:
January 12, 2016
Date of Patent:
October 24, 2017
Assignee:
BIOMARIN PHARMACEUTICAL INC.
Inventors:
James R. Rusche, Norton P. Peet, Allen Hopper
Abstract: Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. Phase invertible compositions in accordance with the invention are prepared by combining a liquid proteinaceous substrate and a liquid crosslinking composition, where the liquid crosslinking composition includes a macromolecular crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications.
Type:
Grant
Filed:
February 11, 2014
Date of Patent:
October 17, 2017
Assignee:
Mallinckrodt Pharma IP Trading D.A.C.
Inventors:
Ronald Dieck, Ian J. Handley, Neil Winterbottom, Joanna Wong
Abstract: An artificial tears solution combination is composed mainly of an anti-inflammation and anti-oxidation material, a liquid viscosity-enhancing agent, and an artificial tears solution. The artificial tears solution combination is capable keeping moisture, and meanwhile having anti-inflammation and anti-oxidation capabilities. As such, it can prolong the liquid retention on ocular surfaces, to effective reduce the repeated dosing, and shorten the schedule for the dry eye syndrome.
Abstract: New methods of treating schizophrenia and schizoaffective disorder by administration of pharmaceutical compositions comprising an antipsychotic compound and a VMAT2 inhibitor to a subject in need thereof are provided.
Abstract: Disclosed herein is the use of manganese, iron, cobalt, or nickel complexes containing tridentate pyridine di-imine ligands as hydrosilylation catalysts. These complexes are effective for efficiently catalyzing hydrosilylation reactions, as well as offering improved selectivity and yield over existing catalyst systems.
Type:
Grant
Filed:
December 14, 2011
Date of Patent:
October 10, 2017
Assignees:
MOMENTIVE PERFORMANCE MATERIALS INC., PRINCETON UNIVERSITY
Inventors:
Keith James Weller, Crisita Carmen H. Atienza, Julie Boyer, Paul Chirik, Johannes G. P. Delis, Kenrick Lewis, Susan A. Nye
Abstract: The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
Type:
Grant
Filed:
May 4, 2012
Date of Patent:
October 3, 2017
Assignee:
RHIZEN PHARMACEUTICALS SA
Inventors:
Dhanapalan Nagarathnam, Swaroop Kumar V. S. Vakkalanka, Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Prashant Kashinath Bhavar
Abstract: The invention relates to formulations containing liquid ester quats and/or imidazolinium salts and polymer thickeners and to the use thereof.
Type:
Grant
Filed:
September 22, 2015
Date of Patent:
September 19, 2017
Assignee:
EVONIK DEGUSSA GMBH
Inventors:
Peter Schwab, Ursula Westerholt, Uta Kortemeier, Jochen Kleinen, Christian Hartung, Hans-Juergen Koehle
Abstract: The present invention is a novel process for the preparation of chalcogenone compounds by conversion of ionic liquids and salts comprising nitrogen-containing heterocyclic cations and basic anions to the corresponding nitrogen-containing heterocyclic chalcogenones by reaction with elemental chalcogens.
Type:
Grant
Filed:
March 30, 2010
Date of Patent:
September 5, 2017
Assignee:
Petroliam Nasional Berhad
Inventors:
Robin Don Rogers, John Holbrey, Hector Rodriguez
Abstract: The invention provides safe and efficacious treatments for Female Sexual Disorders, genitopelvic pain/penetration disorders, vulvovaginal atrophy, vestibulodynia, dyspareunia, sexual interest/arousal disorder, low female libido, and female orgasmic disorder.
Abstract: The present invention relates to compositions of pharmaceutical agents in combination with additional pharmaceutical agents in a mixture of polyethylene glycol, polyvinylpyrrolidone, and propylene glycol and a process of making the compositions.
Type:
Grant
Filed:
February 4, 2016
Date of Patent:
August 29, 2017
Assignee:
Pfizer Inc.
Inventors:
Gary Robert Agisim, Robert Alan Friedline, Shivangi Akash Patel, Cesar Ivan Sertzen, Vanessa Rose Shepperson
Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
Type:
Grant
Filed:
February 25, 2016
Date of Patent:
August 29, 2017
Assignee:
SK BIOPHARMACEUTICALS CO., LTD.
Inventors:
Chun Eung Park, Young Koo Jang, Yong Je Shin, Ji Yeon Kim, Seung Mo Ham, Yong Gil Kim, Hye Kyung Min, Soo Bong Cha, Hyo Jun Jung, Ju Young Lee, Seung Nam Han, Jin Yong Chung, Eun Ju Choi, Chan Mi Joung, Jong Sil Park, Ji Won Lee, Nahm Ryune Cho, Eun Ju Ryu, Cheol Young Maeng
Abstract: Methods of increasing tonic inhibition in a subject in need thereof, for example a subject with Fragile X syndrome or Angelman syndrome are disclosed. Methods of treating secondary insomnia in a subject with a neurodegenerative disease or disorder are also disclosed.